Abbott Laboratories (ABT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for April 25, 2025, with virtual participation and voting options for shareholders of record as of February 26, 2025.

• Total shareholder return (TSR) outperformed peer median over one- and five-year periods, with 5% and 42% returns, respectively.

• $5.1 billion returned to shareholders in 2024; 7.3% dividend increase for 2025, marking 53 consecutive years of dividend growth.

• Robust innovation pipeline and $2.2 billion invested in capital projects in the past year.

Voting matters and shareholder proposals

• Shareholders to vote on: election of 12 directors, ratification of Ernst & Young LLP as auditors, and advisory approval of executive compensation.

• Board recommends voting FOR all director nominees, auditor ratification, and executive compensation.

• Shareholder proposals for the 2026 meeting must be received by November 14, 2025.

Board of directors and corporate governance

• Board consists of 12 nominees, 11 of whom are independent; 50% women, 25% racial/ethnic diversity.

• Lead Independent Director has significant oversight responsibilities, including annual CEO evaluation and shareholder engagement.

• Annual board, committee, and director evaluations; six new independent directors added since 2018.

• Board committees (Audit, Compensation, Nominations and Governance, Public Policy) are fully independent.